NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, appointed Ronald A. Martell as president, CEO and a member of the board, according to a news release.
Mr. Martell previously served as CEO at Poniard Pharmaceuticals. Earlier, he worked at Imclone Systems, where he led the launch and initial commercialization of oncology drug Erbitux. Mr. Martell has also worked at Genentech, where he led the commercial launch of cancer drugs Rituxan and Herceptin.
Related Articles on Pain Management:
16 New Pain Management Facility Openings in 2011
What Technology or Practice Management Tool Do Pain Management Practices Need to Adopt in 2012? 5 Physician Responses
New Regulations Expected to Boost Sales of BioDelivery Sciences International's Pain Relief Patch
Mr. Martell previously served as CEO at Poniard Pharmaceuticals. Earlier, he worked at Imclone Systems, where he led the launch and initial commercialization of oncology drug Erbitux. Mr. Martell has also worked at Genentech, where he led the commercial launch of cancer drugs Rituxan and Herceptin.
Related Articles on Pain Management:
16 New Pain Management Facility Openings in 2011
What Technology or Practice Management Tool Do Pain Management Practices Need to Adopt in 2012? 5 Physician Responses
New Regulations Expected to Boost Sales of BioDelivery Sciences International's Pain Relief Patch